Business Context and Reporting Period
Company: BioSig Technologies, Inc. (Note: Input metadata referenced "Streamex Corp.", but the filing is for BioSig Technologies, Inc., which acquired Streamex Exchange Corporation on May 28, 2025).
Reporting Period: Quarterly period ended June 30, 2025 (Form 10-Q).
Business Overview: BioSig is a medical device technology company developing the PURE EP™ Platform for cardiac arrhythmia ablation. On May 28, 2025, the Company completed the acquisition of Streamex Exchange Corporation, a software development firm focused on digital tools for commodity trading and finance. The Company operates as a single reportable segment.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | As of June 30, 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss (Attributable to Common Shareholders) | $(20,374,000) | $(23,190,000) | N/A |
| Net Loss Per Share (Basic & Diluted) | $(0.74) | $(0.95) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $2,820,000 |
| Working Capital | N/A | N/A | $(110,199,000) Deficit |
| Total Assets | N/A | N/A | $109,721,000 |
| Total Liabilities | N/A | N/A | $113,200,000 |
| Derivative Liability (Streamex Exchangeable Shares) | N/A | N/A | $105,498,000 |
| Goodwill | N/A | N/A | $58,692,000 |
Material Changes vs. Prior Period
- Acquisition Impact: The most significant change is the acquisition of Streamex Exchange Corporation. This resulted in the recognition of $58.7 million in Goodwill and $47.9 million in Intangible Assets (Trade Name, Developed Technology, Legal Framework). Consequently, Total Assets increased from $842,000 (Dec 31, 2024) to $109.7 million.
- Liabilities: Total liabilities surged from $2.3 million to $113.2 million, driven primarily by the classification of $105.5 million in Exchangeable Shares as a derivative liability due to pending shareholder approval requirements.
- Operating Expenses: General and Administrative (G&A) expenses increased 303% for the three months ended June 30, 2025, compared to the prior year period. This was due to $12.1 million in stock-based compensation (including accelerated vesting for the former CEO) and $6.0 million in finder's fees related to the Streamex acquisition.
- Revenue: Revenue remained negligible ($0) for the current period, compared to $13,000 in the prior year quarter.
- Stock-Based Compensation: Significant non-cash expenses were recorded, including $14.2 million in G&A and $25,000 in R&D for the six months ended June 30, 2025.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The Company has a working capital deficit of approximately $110 million and raised substantial doubt about its ability to continue as a going concern. It requires additional financing to fund operations.
- Derivative Liability Contingency: The $105.5 million derivative liability is contingent on shareholder approval. If approval is not obtained by November 28, 2025, the exchange ratio adjusts from 1.0 to 1.25, potentially increasing the liability value.
- Subsequent Financing: Following the reporting period, the Company entered into a Senior Secured Convertible Debenture agreement (up to $100 million) and a Standby Equity Purchase Agreement (SEPA) for up to $1 billion. Additionally, an August 2025 public offering generated approximately $13.6 million in net proceeds.
- Internal Controls: Management concluded that internal controls over financial reporting were not effective as of June 30, 2025, citing material weaknesses in stock-based compensation accounting, period-end review processes, segregation of duties, and accounting for business combinations.
- Unusual Items: The period included $6.0 million in finder's fees and significant stock-based compensation acceleration related to the resignation of the former CEO and the Streamex acquisition.
Investor Verification Checklist
- Shareholder Approval Status: Verify if the required shareholder vote to lift the 19.99% conversion cap on Streamex Exchangeable Shares has been scheduled or completed, as this dictates the final liability value.
- Liquidity Runway: Assess the sufficiency of the $2.8 million cash balance against the $110 million working capital deficit and the timeline for closing the subsequent $100 million debenture and $1 billion SEPA.
- Internal Control Remediation: Review the specific remediation plan for the identified material weaknesses in financial reporting and stock-based compensation accounting.
- Streamex Integration: Evaluate the progress of Streamex's pre-revenue platform development and the timeline for generating revenue from tokenized commodities.
- Series C Preferred Stock: Monitor the $105,000 stated value of Series C Preferred Stock, which carries redemption triggers that could create immediate liquidity obligations.